Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 446 across all filing types
Latest filing 2024-08-22 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
益方生物2024年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2024 年半年度报告摘要' which translates to '2024 Semi-Annual Report Summary'. It contains detailed financial data such as total assets, net profit, revenue, and shareholder information for the half-year period. The text includes management discussion of risks, financial performance, and operational highlights typical of an interim or quarterly report. The document length is 4482 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or a link to a report. Therefore, it is classified as an Interim / Quarterly Report (IR). H1 2024
2024-08-22 Chinese
益方生物2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2024 年半年度报告" which translates to "2024 Semi-Annual Report". It contains detailed financial data, management discussion and analysis, company business overview, product pipeline, risk factors, and other comprehensive information typical of an interim or quarterly report. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. It includes financial statements, management's discussion and analysis, and other substantive financial and operational data for the first half of 2024. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-22 Chinese
益方生物关于使用部分闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Yifang Bio-Technology (Shanghai) Co., Ltd. regarding the use of part of idle raised funds for cash management. It details the board meeting approval, the amount and purpose of the cash management, risk controls, and compliance with regulatory requirements. The document does not contain financial statements or detailed financial results but is a disclosure about the company's financing fund usage and investment plans. It is not an annual or interim report, earnings release, or audit report. It is a regulatory announcement about capital usage and cash management of raised funds, fitting the category of Capital/Financing Update (CAP). The document length is under 5,000 characters, but it is a substantive announcement, not merely a report publication notice or certification. Therefore, the best classification is CAP with high confidence.
2024-08-22 Chinese
益方生物关于召开2024年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2024 half-year performance explanation meeting (业绩说明会) for investors. It specifies the date, time, location, and participation method for the meeting, which is intended to discuss the company's half-year operating results and financial indicators. The document does not contain actual financial statements or detailed financial analysis but rather serves as a notice for an upcoming investor presentation event. It also mentions that the half-year report will be published on August 23, 2024, but this document itself is not the report. Therefore, this document fits the category of an Investor Presentation (IP) announcement rather than an Interim Report (IR) or Earnings Release (ER). The document length is short (1472 characters), and it is clearly an announcement for a meeting to discuss financial results, not the results themselves.
2024-08-16 Chinese
益方生物关于持股5%以上股东部分股份质押的公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding the pledge of shares by a shareholder holding more than 5% of the company's shares. It details the number of shares pledged, the proportion of total shares, and the terms of the pledge. There is no indication of financial statements, management discussion, or other report content. The document is a regulatory announcement about a major shareholding event, specifically a share pledge by a significant shareholder. This fits the category of Major Shareholding Notification (MRQ). The document length is short and focused solely on this share pledge event, confirming it is not a full report or financial statement.
2024-08-06 Chinese
益方生物首次公开发行部分战略配售限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement regarding the listing and circulation of restricted shares from the company's initial public offering (IPO) strategic placement shares. It details the number of shares becoming freely tradable after the lock-up period, the dates involved, and compliance with regulatory approvals. The document does not contain financial statements or detailed financial performance data but rather focuses on the share circulation event and related shareholder commitments. It is a regulatory announcement about share listing and circulation, not a full financial report or earnings release. Therefore, it fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock listing, or capital changes.
2024-07-17 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.